ライフサイエンスコーパス: orthosteric

1 n four groups (interfacial, rim, allosteric, orthosteric) according to their properties and spatial l

2 tagonize) the receptor, and the third is the orthosteric activation (agonist) site.

3 ides crucial insights into the mechanisms of orthosteric activation and allosteric modulation of musc

4 rthosteric agonists, Tyr-93 can conduct both orthosteric activation and desensitization among the sub

5 vealed mechanistic information regarding the orthosteric activation by 5-HT and by the partial agonis

6 inetic analysis revealed that allosteric and orthosteric activation mechanisms can be described by th

7 hese mutations have no significant effect on orthosteric activation of 5-HT3ARs by 5-HT.

8 identify Tyr-93 as an essential element for orthosteric activation, because Y93C mutants are insensi

9 eting of SHP2 was hampered by the failure of orthosteric active-site inhibitors to achieve selectivit

10 , and mutagenesis results suggested that the orthosteric agonist 5'-N-ethylcarboxamidoadenosine binds

11 he maximum response evoked by the endogenous orthosteric agonist 5-HT, respectively).

12 ic activation in addition to potentiation of orthosteric agonist activity, which identifies it as an

13 nous allosteric modulator of MOPr and alters orthosteric agonist affinity and efficacy.

14 ta(2)-adrenergic receptor in complex with an orthosteric agonist and compound-6FA, a positive alloste

15 ntiated macroscopic currents elicited by the orthosteric agonist and directly elicited currents with

16 An allosteric modulator and an orthosteric agonist bind simultaneously to the receptor

17 , improved metabolic stability, and enhanced orthosteric agonist binding (CP55,940).

18 anges are coupled between the extracellular, orthosteric agonist binding domain and the transmembrane

19 These positive allosteric modulators of orthosteric agonist binding nonetheless antagonized the

20 flytrap domain, a region generally known for orthosteric agonist binding.

21 o the transmission of cooperativity with the orthosteric agonist carbachol.

22 to the receptor only in the presence of the orthosteric agonist carbachol.

23 e positively modulate the binding of the CB1 orthosteric agonist CP55,940 while exhibiting an antagon

24 positive allosteric modulator of binding of orthosteric agonist CP55,940.

25 sidues near the TM4-ECL2 juncture influenced orthosteric agonist efficacy.

26 ffects on the modulation of responses to the orthosteric agonist l-quisqualate and the allosteric mod

27 intracellular Ca(2+) responses evoked by the orthosteric agonist l-quisqualate.

28 Residues involved in cooperativity with the orthosteric agonist NECA were different in PD81723 and V

29 m the mushroom Amanita muscaria and a potent orthosteric agonist of the GABA(A) receptor.

30 eptors were determined in complex with their orthosteric agonist peptides, however, little is known a

31 Ms), and 5) compounds that have no effect on orthosteric agonist responses but block allosteric modul

32 duce signaling and also selectively traffics orthosteric agonist signaling via the ERK phosphorylatio

33 tion that were significantly up-regulated by orthosteric agonist stimulation.

34 like PNU-120596, require coapplication of an orthosteric agonist to produce large channel activations

35 M4 muscarinic acetylcholine receptor (mAChR) orthosteric agonist xanomeline (1) and the putative M1 m

36 ydroxylpropyl]cyclohe xan-1-ol (CP55,940, an orthosteric agonist) while at the same time decreasing i

37 his work expands the characterization of the orthosteric agonist, iperoxo, at the M(4) receptor, and

38 couple to PLD not only failed to potentiate orthosteric agonist-induced LTD but also blocked M(1)-de

39 of mGluR1alpha is adjacent to the site where orthosteric agonists and antagonists bind on the extrace

40 interact either directly or indirectly with orthosteric agonists and antagonists.

41 Some orthosteric agonists bind to multiple sites on a recepto

42 pha7 mutant C190A, which is not activated by orthosteric agonists but is effectively activated by GAT

43 llosteric enhancers slow the dissociation of orthosteric agonists but not antagonists.

44 ion, because Y93C mutants are insensitive to orthosteric agonists but respond to GAT107.

45 d in vivo pharmacological actions of the CB1 orthosteric agonists CP55,940 and N-arachidonoylethanola

46 esis studies indicate that the compounds are orthosteric agonists despite the absence of a carboxylat

47 tivity binding of [(3)H]LY2119620 with mAChR orthosteric agonists detects significant changes in Bmax

48 The receptors were activated by the orthosteric agonists GABA or beta-alanine, the allosteri

49 interactions at receptors that bind multiple orthosteric agonists in a cooperative manner.

50 in penetrant, increased the potency of these orthosteric agonists in mouse behavioral assays indicati

51 Orthosteric agonists induce transitions between these co

52 increase the affinity and/or efficacy of the orthosteric agonists leu-enkephalin, SNC80 and TAN67, as

53 s of alpha7 that are insensitive to standard orthosteric agonists like acetylcholine.

54 metabotropic glutamate receptors (mGluRs) or orthosteric agonists of mGluR2/3.

55 Clinical development of catechol-based orthosteric agonists of the dopamine D1 receptor has thu

56 responsive manner, whereas M1 allosteric and orthosteric agonists showed weak affinity (>30 muM).

57 acetylcholine receptor (nAChR) activation by orthosteric agonists with intrinsic allosteric agonist a

58 toxin, a positive allosteric modulator, and orthosteric agonists, at 3.8 to 4.1 angstrom resolution.

59 In contrast to orthosteric agonists, LY3154207 showed a distinct pharma

60 the restraints placed on the requirement for orthosteric agonists, Tyr-93 can conduct both orthosteri

61 ffects observed with nonselective muscarinic orthosteric agonists.

62 activate wild-type alpha7 in the absence of orthosteric agonists.

63 e adenosine A1 receptor amplify signaling by orthosteric agonists.

64 d was positively cooperative with muscarinic orthosteric agonists.

65 Undesirable side effects associated with orthosteric agonists/antagonists of cannabinoid 1 recept

66 Although PAMs must work in concert with "orthosteric" agonists, compounds such as GAT107 ((3aR,4S

67 d differential potentiation depending on the orthosteric-allosteric pairing, with the largest coopera

68 ed to the discovery of a new class of hybrid orthosteric/allosteric (bitopic) molecules.

69 Here we use the model of bitopic orthosteric/allosteric (i.e. dualsteric) agonists for mu

70 ive purely allosteric and the active bitopic orthosteric/allosteric binding pose.

71 Our data show that both orthosteric and allosteric activation of alpha7 nAChR re

72 At the single-channel level, activation by orthosteric and allosteric agonists appeared as openings

73 and steady-state activity in the presence of orthosteric and allosteric agonists, and the inhibitory

74 ent times have seen the description of novel orthosteric and allosteric agonists.

75 Both orthosteric and allosteric antagonists of the group II m

76 ts into P2Y1R should enable discovery of new orthosteric and allosteric antithrombotic drugs with red

77 ata and evidence for the binding kinetics of orthosteric and allosteric AR ligands.

78 of many GPCRs and the identification of both orthosteric and allosteric binding sites have provided f

79 eptor structures, reveals differences in the orthosteric and allosteric binding sites that contribute

80 tations, as well as functional regulation by orthosteric and allosteric effectors.

81 )-imido]triphosphate, suggests that both the orthosteric and allosteric ligands can alter the populat

82 ammalian cells, extracellular protons act as orthosteric and allosteric ligands for multiple receptor

83 )-epsilon-methionine upon binding to various orthosteric and allosteric ligands having a range of eff

84 nd access and binding mechanisms for several orthosteric and allosteric ligands of class A and class

85 Structurally diverse orthosteric and allosteric ligands, including newly desi

86 nalysis of P2X4R kinetics and elucidates the orthosteric and allosteric mechanisms regulating its cha

87 recent progress in the field, covering both orthosteric and allosteric modes of activation, discusse

88 ble high-throughput screens to identify both orthosteric and allosteric PLC inhibitors.

89 of residues that form a network linking the orthosteric and allosteric sites of the M4 receptor, whi

90 These data suggest the orthosteric and allosteric sites on CHRMs respond differ

91 gagement (i.e., concomitant association with orthosteric and allosteric sites) and that the compound

92 te the transmission of cooperativity between orthosteric and allosteric sites.

93 dent kinase 2, which successfully identifies orthosteric and allosteric sites.

94 rent features for ligand binding pockets and orthosteric and allosteric sites.

95 g two pharmacophores to simultaneously adopt orthosteric and allosteric topography within a G protein

96 Here, we investigate the effect of an orthosteric and an allosteric antagonist on CCR2 dynamic

97 Most ligands in the D3R(APO) model span both orthosteric and extended pockets and behave as antagonis

98 of substitutions in the LBD on coactivator, orthosteric, and allosteric ligand binding.

99 hed the inhibitory effect of the mGluR1alpha orthosteric antagonist (S)-alpha-methyl-4-carboxyphenylg

100 ration binding studies at the M2R, using the orthosteric antagonist atropine to determine unspecific

101 R agonist, an effect inhibited by the GLP-1R orthosteric antagonist exendin(9-39) (Ex(9-39)).

102 harmacological profile, decreased binding of orthosteric antagonist N-methylscopolamine to human M1-

103 Point mutations ruled out an orthosteric antagonist site.

104 The orthosteric antagonists quinuclidinyl benzilate (QNB) an

105 o date were obtained with receptors bound to orthosteric antagonists, and only a few structures bound

106 he side effects associated with CB1 receptor orthosteric antagonists, negative allosteric modulators

107 other D2R "privileged structures" generated orthosteric antagonists.

108 Orthosteric beta-adrenergic receptor antagonists, known

109 direct interactions with residues within the orthosteric binding area but also with remote residues.

110 A(3)R antagonist and the description of its orthosteric binding mode.

111 rved NMR confirms 1 binds PPARgamma with two orthosteric binding modes and to an allosteric site.

112 eveal that extracellular loop 2 occupies the orthosteric binding pocket and operates as a built-in ag

113 firm that LY2119620 does not compete for the orthosteric binding pocket at any of the five muscarinic

114 utation of amino acid residues that form the orthosteric binding pocket caused a loss of carbachol re

115 nomeric and the dimeric compound bind to the orthosteric binding site (apparent Kd: 0.87 and 0.31 nM,

116 nt of bitopic ligands aimed at targeting the orthosteric binding site (OBS) and a metastable binding

117 subtle differences in the highly homologous orthosteric binding site (OBS) differentially affect D2R

118 The existence of a high affinity primary orthosteric binding site (S1) and a low affinity seconda

119 olves simultaneous interaction with both the orthosteric binding site and the allosteric binding site

120 ne analogs bind at the monoamine transporter orthosteric binding site by adopting one of two mutually

121 ligand binding on the local structure of the orthosteric binding site by agonists, competitive antago

122 loited a single amino acid difference in the orthosteric binding site by using molecular docking and

123 Mutations within the orthosteric binding site caused similar reductions in af

124 Here, we investigate the pharmacology of the orthosteric binding site in GluD2 by examining the activ

125 s were made in the complementary side of the orthosteric binding site in loop D (Y87F and Q89R), loop

126 oop receptors, involving an expansion of the orthosteric binding site in the extracellular domain tha

127 e loop C, D, and E regions that surround the orthosteric binding site in the h5-HT(3A) receptor, we i

128 moterol and two serine residues in H5 at the orthosteric binding site of beta(1)AR, and find that for

129 2), a compound supposed to interact with the orthosteric binding site of dopamine receptors, was actu

130 erminants of gabazine for binding to (i) the orthosteric binding site of the GABA(A) receptor and (ii

131 ex with TK40 and show that TK40 binds to the orthosteric binding site of the GluN1 subunit with a bin

132 rmational changes in regions surrounding the orthosteric binding site of the human 5-HT(3A) (h5-HT(3A

133 r antagonism by ligands interacting with the orthosteric binding site of the receptor to incorporate

134 onal changes in the extracellular region and orthosteric binding site than observed in the active sta

135 ically prevents dissociation of NMS from the orthosteric binding site.

136 nterface on the complementary surface of the orthosteric binding site.

137 d a 24 to 42% reduction in the volume of the orthosteric binding site.

138 activated by extracellular ATP through three orthosteric binding sites and allosterically regulated b

139 ive "methyl scan" approach, we show that the orthosteric binding sites for acetylcholine and nicotine

140 ules are potentially able to interact at two orthosteric binding sites of a heterodimer simultaneousl

141 tor binding site partially overlaps with the orthosteric binding sites of class A GPCRs but is more r

142 of bitopic engagement of the allosteric and orthosteric binding sites of the receptor.

143 ation follows the binding of agonists to the orthosteric binding sites of the receptor.

144 and allosterism for receptors with multiple orthosteric binding sites, and demonstrate that such mod

145 the similarity between (adenosine receptors) orthosteric binding sites, obtaining highly selective an

146 r prevent the synergy between allosteric and orthosteric binding sites, so that these mutants can als

147 alidated protein targets with allosteric and orthosteric binding sites, using five chemically distinc

148 GPCR ligands due to the high conservation of orthosteric binding sites.

149 ned by independent actions on the respective orthosteric binding sites.

150 logous GPCR detections through structure and orthosteric binding-site comparisons.

151 ir gating through a mechanism independent of orthosteric binding.

152 ructure of CCR2 in a ternary complex with an orthosteric (BMS-681) and allosteric (CCR2-RA-[R]) antag

153 of bipharmacophoric ligands composed of the orthosteric building blocks iperoxo and 1 linked to allo

154 ellular site, and atropine or scopolamine as orthosteric building blocks, both connected by a hexamet

155 nabinoid deactivation (JZL184, URB597) or an orthosteric cannabinoid agonist (WIN55,212-2).

156 rs of endocannabinoid deactivation and/or an orthosteric cannabinoid agonist.

157 lactic inactivation of CD11b/CD18, using the orthosteric CD11b/CD18 inhibitor mAb107, improves microv

158 patially distinct sites: nucleotide MRS2500 (orthosteric, contacting the helical bundle) and urea BPT

159 we show progressive disruption of individual orthosteric contacts in the ligand binding sites, allowi

160 lation mediated via beta-arrestin unlike the orthosteric CP55,940 that does so in a G protein-depende

161 f endogenous agonists that interact with the orthosteric domain on the receptor.

162 We dub these orthosteric drivers.

163 sp52(2.50) as an allosteric link between the orthosteric drug binding site and the intracellular sign

164 prospect with many potential advantages over orthosteric drugs.

165 eceptor cavity that can bind allosteric (non-orthosteric) drugs.

166 ds were confirmed to be potent and selective orthosteric FFA2 agonists.

167 e congener 31, which retains a high-affinity orthosteric fragment (5d, D(3)R K(i) = 23.9 nM), 1 was f

168 Fragmentation of 1 revealed orthosteric fragment 5a to express an unusually low D(3)

169 e linkers alone decreased the potency of the orthosteric fragment.

170 que rationale for implementing weakly potent orthosteric fragments into D(3)R ligand systems to minim

171 ine interacts with the high-affinity GHB and orthosteric GABA(A) receptor binding sites differently a

172 verlap of binding sites for several pairs of orthosteric (GABA, beta-alanine, and piperidine-4-sulfon

173 In the present study, the orthosteric GABAA receptor (GABAAR) ligand 4,5,6,7-tetra

174 The orthosteric GABAB receptor agonist baclofen has been sho

175 We find that orthosteric "head" groups with small 7-substituents were

176 tic sites make them a challenging target for orthosteric inhibition.

177 ptor, and offers advantages over traditional orthosteric inhibition.

178 ionalize oligonucleotides with biotin and an orthosteric inhibitor of the eukaryotic initiation facto

179 Pure orthosteric inhibitors of alphaIIbbeta3 may thus provide

180 ones, also known as oncohistones, are potent orthosteric inhibitors of specific Su(var)3-9, Enhancer-

181 y selective alternative to conventional TYK2 orthosteric inhibitors.

182 having a significant role in contributing to orthosteric ligand affinity and signaling for various G

183 ECL2-TM3 disulfide bond selectively affected orthosteric ligand affinity, whereas a cluster of five r

184 ct to ligand displacement but did not change orthosteric ligand affinity.

185 ence that was based upon the efficacy of the orthosteric ligand and can be explained using the Monod-

186 Both dissociation and binding of an orthosteric ligand are observed in a single all-atom GPC

187 or redox state profoundly influences beta2AR orthosteric ligand binding and downstream function.

188 study highlights a key role for ECL2 in A1AR orthosteric ligand binding and receptor activation.

189 hanges of agonist-bound beta(1)AR around the orthosteric ligand binding pocket indicate that the full

190 ffects of sodium ions and amiloride, whereas orthosteric ligand binding was decreased.

191 nd in this sodium ion site and can influence orthosteric ligand binding.

192 suggesting additional allosteric effects on orthosteric ligand efficacy.

193 perativity and negative allosteric effect on orthosteric ligand maximal signaling response.

194 2 to explore the role of this domain on A1AR orthosteric ligand pharmacology.

195 The sensitivity of an orthosteric ligand to BMS-986122 was strongly correlated

196 electivity problem by combining (linking) an orthosteric ligand with an allosteric modulator, theoret

197 exposed active conformation and occupies the orthosteric ligand-binding pocket enabled by a conformat

198 stin-biased signaling from occupation of the orthosteric ligand-binding pocket.

199 Also, the orthosteric ligand-binding site becomes the initiator re

200 1) reveals that, despite conservation of the orthosteric ligand-binding site residues, there are nota

201 potential biomolecular target, from both an orthosteric (ligand-binding sites) and allosteric (locat

202 ule, approximately 15 A from the classical, 'orthosteric' ligand-binding site.

203 a a different binding site than the natural (orthosteric) ligand site and hence form a conceptually d

204 voked signaling but also the actions of both orthosteric ligands and allosteric modulators on mGluR1a

205 estibule that overlaps with a region used by orthosteric ligands as they transit into the canonical A

206 can be differentially stabilized not only by orthosteric ligands but also by allosteric ligands actin

207 Cell-permeable orthosteric ligands can assist folding of G protein-coup

208 However, developing M1 mAChR-selective orthosteric ligands has proven challenging.

209 the coupling between PAMs and the binding of orthosteric ligands requires tryptophan 55 (Trp-55), whi

210 renergic receptor (beta2AR) upon exposure to orthosteric ligands with different efficacies, in the ab

211 Interaction of orthosteric ligands with extracellular domain was descri

212 GABA(B1) recognizes orthosteric ligands(7,8), while GABA(B2) couples with G

213 hese compounds do not compete for binding of orthosteric ligands, but indeed the R isomer increased t

214 7569, offer enormous potential as drugs over orthosteric ligands, but their mechanistic, structural,

215 compound has no effect on the binding of the orthosteric ligands, implying its allosteric mode of act

216 domain (ECD) conformations in the absence of orthosteric ligands, which has limited our understanding

217 Unlike orthosteric ligands, which tonically activate or inhibit

218 binding competition with serotonin or other orthosteric ligands.

219 ostatic repulsion between the allosteric and orthosteric ligands.

220 and mechanisms governing cooperativity with orthosteric ligands.

221 h drugs that act as allosteric modulators of orthosteric ligands.

222 122, with a chemically diverse range of MOPr orthosteric ligands.

223 efficacy for both selective and prototypical orthosteric ligands.

224 c benefits avoiding inherent side effects of orthosteric ligands.

225 dicted not only to target active sites in an orthosteric manner, but also to act through allosteric m

226 Identification of orthosteric mGlu(2/3) receptor agonists capable of discr

227 eveal how ATP/Mg(2+) functions as a negative orthosteric modulator.

228 ructural information about the nature of the orthosteric muscarinic binding site (the conventional ac

229 ntrations up to 1 mM did not compete for the orthosteric nAChR binding site labeled by [(3)H]epibatid

230 nd 5b binds to pH sensor of ASIC1a acting as orthosteric noncompetitive antagonist.

231 retase presents several hot spots for either orthosteric or allosteric inhibition of catalytic activi

232 ologic activity induced by ligand binding to orthosteric or allosteric sites on a G protein-coupled r

233 e or negative, depending upon the allosteric-orthosteric pair, and they arose from interactions withi

234 In contrast, orthosteric PAR1 antagonists such as vorapaxar inhibit a

235 ng modes for these ligands, which occupy the orthosteric pocket and an extended binding pocket close

236 l)benzenesulfonamide (1, T2384) revealed two orthosteric pocket binding modes attributed to a concent

237 lidates the suitability of the agonist-bound orthosteric pocket in the MT receptor structures for the

238 , Tyr5.47, and Tyr6.48 and another above the orthosteric pocket lined by Asp2.65 and Tyr7.32.

239 CL12 N terminus for optimal docking into the orthosteric pocket of CXCR4 and suggests that the CC/CXC

240 o terminus of the chemokine inserts into the orthosteric pocket of the GPCR, causing conformational c

241 inhibits chemokine binding by occupying the orthosteric pocket of the receptor in a previously unsee

242 the large extracellular domain (ECD) and the orthosteric pocket, inducing conformational changes in t

243 he high degree of structural homology in the orthosteric pocket, particularly for GPCRs within a sing

244 mation and binds to the receptor deep in the orthosteric pocket, stabilizing a network of extracellul

245 nt binding poses are revealed for ARC in the orthosteric pocket.

246 lly, NRs are targeted via their hydrophobic, orthosteric pocket.

247 g the size and amino acid composition of the orthosteric pocket.

248 ues in the intracellular, extracellular, and orthosteric pockets is significantly weakened upon sodiu

249 e potency and a distinct binding mode in the orthosteric PPARgamma ligand-binding site.

250 Drugs targeting the orthosteric, primary binding site of G protein-coupled r

251 diated allosteric effect is dependent on the orthosteric probe that is used.

252 es was assessed by their ability to displace orthosteric radioligand [(3)H]4-(2-((7-amino-2-(furan-2-

253 ptor binding with a series of allosteric and orthosteric radioligands at structurally related CCK1R a

254 t of affinity for allosteric modulators with orthosteric radioligands, which has so far been the most

255 Delta(9)-tetrahydrocannabinol and other CB1 orthosteric receptor agonists remain limited because of

256 ligands that bind allosterically outside the orthosteric receptor binding pocket.

257 Czon1107 acted at a site distinct from the orthosteric receptor site.

258 ML290 did not directly compete with orthosteric relaxin binding and did not affect binding k

259 of IBMX based on their interactions with the orthosteric residues of PDE8.

260 y distinct from that of previously described orthosteric RORgammat ligands.

261 ls the entry and efflux of agonists from the orthosteric site and agonist binding elicits a conformat

262 echanism, interacting concomitantly with the orthosteric site and part of an allosteric site.

263 the two novel bitter blockers share the same orthosteric site as the agonist quinine.

264 tes because their activity requires that the orthosteric site be occupied by an agonist, thereby conf

265 the expected change in affinity of the CHRM1 orthosteric site for acetylcholine in human cortex.

266 lthough it is well established that the A1AR orthosteric site is located within the receptor's transm

267 to agonists or antagonists that bind to the orthosteric site of the receptor.

268 r the development of compounds that bind the orthosteric site of this receptor.

269 The contacts found for the orthosteric site satisfy all the requirements deduced fr

270 a binding pose predicted to extend from the orthosteric site up toward a putative allosteric site bo

271 eveals the orientation of granisetron in the orthosteric site with unambiguous density for interactin

272 idues to recognize diverse bile acids in the orthosteric site, a putative second bile acid-binding si

273 e extracellular entrance, in addition to the orthosteric site, allowed us to obtain 5-HT7R antagonist

274 lu4, mGlu6, and mGlu8 receptors with its own orthosteric site, and (2) that chloride is not an agonis

275 compounds are compatible with binding to the orthosteric site, further motivating the selective press

276 It binds several compounds in its orthosteric site, including the endocannabinoids, arachi

277 ng of a neurotransmitter to an extracellular orthosteric site, located at the interface of two adjace

278 s between an allosteric site and its coupled orthosteric site.

279 118925 and anthraquinones likely bind to the orthosteric site.

280 prior to entry into the canonical TM bundle orthosteric site.

281 ands as they transit into the canonical A1AR orthosteric site.

282 (2)R, and M(4)R) confirmed occupation of the orthosteric site.

283 nd-binding site blocking the entrance to the orthosteric site.

284 residues important for binding in the A(3)R orthosteric site.

285 cence changes for all ligands binding at the orthosteric site.

286 the alpha-Ctx-binding sites overlap with the orthosteric sites at the beta/alpha subunit interface.

287 tion of compounds that directly acted on the orthosteric sites for endogenous ligands.

288 ngest functional group interaction in enzyme orthosteric sites offers a rational starting point for F

289 Orthosteric sites on proteins are formed typically from

290 receptors topographically distinct from the orthosteric sites, so-called allosteric sites, has heral

291 in contrast to the global impact of GABA via orthosteric sites, the force of anaesthetics through all

292 ll activation paradigm via allosteric versus orthosteric sites, we used highly homologous, but homo-o

293 ective and less toxic than those that target orthosteric sites.

294 major advantages of targeting allosteric vs orthosteric sites: extreme selectivity, ability to inhib

295 ed 5-benzyloxygramine as a new N protein PPI orthosteric stabilizer that exhibits both antiviral and

296 We identify orthosteric stabilizers that increase 14-3-3/ERalpha aff

297 However, targeting PAR1 with an orthosteric-tethered ligand binding-site antagonist resu

298 receptors can simultaneously occupy both the orthosteric transmitter binding site and the allosteric

299 t a difference in spatial orientation of the orthosteric tropane moiety translates into a divergent M

300 If (i) affinity, (ii) efficacies, (iii) orthosteric versus allosteric interaction, and (iv) rate